Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
| Business Activity | PASS |
| Debt Ratio | N/A |
| Cash Ratio | N/A |
| Receivables Ratio | N/A |
| Revenue Ratio | N/A |
| Overall | INSUFFICIENT DATA |
$2.4B
3.59
0.995
14
$40.0M
1.16
8.23
0.1%
507
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($33.93, 15 analysts) | |||
| 10 | $202.10 | +$137.20 (68%) | 4.5R |
| 50 | $1,010.50 | +$686.00 (68%) | 4.5R |
| 100 | $2,021.00 | +$1,372.00 (68%) | 4.5R |
- Elevated short interest (8.23 days to cover)
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| ARKG | 0.621 |
| HQH | 0.558 |
| BEAM | 0.542 |
| IWM | 0.524 |
| NRIX | 0.511 |
| Ticker | Correlation |
|---|---|
| SUNC | -0.223 |
| BAES.L | -0.175 |
| SUKOON.AE | -0.159 |
| NMAX | -0.143 |
| MO | -0.138 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.